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Hemoglobin (Hb)-based oxygen carriers (HBOC) have been engineered to replace or
augment the oxygen-carrying capacity of erythrocytes. However, clinical results have
generally been disappointing due to adverse side effects linked to intrinsic heme-
mediated oxidative toxicity and nitric oxide (NO) scavenging. Redox-active tyrosine resi-
dues can facilitate electron transfer between endogenous antioxidants and oxidative
ferryl heme species. A suitable residue is present in the α-subunit (Y42) of Hb, but absent
from the homologous position in the β-subunit (F41). We therefore replaced this residue
with a tyrosine (βF41Y, Hb Mequon). The βF41Y mutation had no effect on the intrinsic
rate of lipid peroxidation as measured by conjugated diene and singlet oxygen formation
following the addition of ferric(met) Hb to liposomes. However, βF41Y signiﬁcantly
decreased these rates in the presence of physiological levels of ascorbate. Additionally,
heme damage in the β-subunit following the addition of the lipid peroxide hydroperoxyoc-
tadecadieoic acid was ﬁve-fold slower in βF41Y. NO bioavailability was enhanced in
βF41Y by a combination of a 20% decrease in NO dioxygenase activity and a doubling of
the rate of nitrite reductase activity. The intrinsic rate of heme loss from methemoglobin
was doubled in the β-subunit, but unchanged in the α-subunit. We conclude that the add-
ition of a redox-active tyrosine mutation in Hb able to transfer electrons from plasma anti-
oxidants decreases heme-mediated oxidative reactivity and enhances NO bioavailability.
This class of mutations has the potential to decrease adverse side effects as one comp-
onent of a HBOC product.
Introduction
Hemoglobin (Hb)-based oxygen carriers (HBOC, colloquially termed ‘blood substitutes’) have the
potential to be transfused in place of packed red blood cells to restore impaired oxygen transport [1].
HBOC offer the potential advantages of universal compatibility, enhanced shelf life, no risk of disease
transmission, enhanced and controllable oxygen delivery, improved rheological properties, and more
reliable availability. They are also available to individuals who cannot receive conventional blood
transfusions for clinical or religious reasons. HBOC have also been used in addition to standard
therapy in attempts to augment oxygen delivery in the microvasculature.
There have been a variety of different approaches to optimize recombinant Hb as a suitable starting
material for a HBOC product [2]. Historically, Olson’s group has been instrumental in introducing a
variety of globin mutants to enhance stability, increase afﬁnity, and decrease nitric oxide (NO) dioxy-
genase activity [2,3]. Nagai and co-workers [4] engineered genetically linked Hb dimers to increase
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vascular retention time and also created new interactions with plasma effectors, such as bicarbonate, to
enhance oxygen ofﬂoading in tissue [5]. Many groups used novel cysteine residues to create sulfhydryl bridges
and stabilize higher order protein structures [6,7].
In a recent review bemoaning the lack of viable approved products, blame was largely placed on side effects
due to the redox reactivity of Hb [1]. However, to date, speciﬁc issues relating to the oxidative stress induced
by recombinant Hb have focused almost entirely on two different areas. First, avoiding signiﬁcant increases in
the autoxidation rate — the conversion of oxyhemoglobin (oxyHb) to methemoglobin (metHb) and superoxide
radical. Secondly, avoiding oxidation during the manufacturing/protein production process; for example, Levine
et al. [8] showed that modifying the His-2 residue could decrease oxidative modiﬁcation in the β-subunit and
suggested that recombinant proteins that maintained their N-terminal methionine could have additional
antioxidative properties [9].
There is a general acceptance [10] that cell-free Hb induces oxidative stress in vivo by reacting with peroxides
(H2O2 or lipid-derived). In the ferrous state (oxy or deoxy), this creates ferryl iron; in the ferric (met) state,
both ferryl iron and a globin radical are produced. Note, given that ferryl Hb is autoreduced back to ferric, the
eventual production of globin radicals is inevitable even if the starting material contains negligible metHb. We
have shown that the plasma antioxidants, ascorbate and urate, act synergistically to maintain extracellular Hb
in a functional state [11].
Following peroxide addition to ferric globins, ascorbate can quantitatively capture both the ferryl iron and
the free radical species [12]. However, kinetic limitations, or a decrease in antioxidant levels, may result in
partial reduction and a consequent increase in tissue oxidative damage. Tyrosine residues are able to act as
redox mediators by one-electron cycling between oxidized (radical) and reduced forms. Indeed, many enzymes,
such as catalases and peroxidases, make use of tyrosine redox centers [13,14]. We have shown that myoglobin
[15] and the Hb α-subunit [16] have electron transfer pathways that are able to enhance the rate of ferryl
reduction by plasma antioxidants. These proteins have a high-afﬁnity saturable pathway where the initial elec-
tron acceptor is a tyrosine residue. The Hb β-subunit lacks such a pathway [16]. Introducing such a pathway
into the β-subunit in the homologous site where one is present in the α-subunit (βF41Y) resulted in enhanced
ferryl reduction in tetrameric Hb [16].
Myoglobin from the sea hare (Aplysia fasciata) lacks any tyrosine residues. Therefore, like the β-subunit of
human Hb, it lacks a high-afﬁnity ferryl reduction pathway. In this model system, we were able to create a
variety of phenylalanine to tyrosine mutations with enhanced electron transfer pathways for ascorbate [17].
Furthermore, in the presence of ascorbate, but not in its absence, these mutants had signiﬁcantly decreased
lipid peroxidation activity compared with the wild-type (wt) protein. The purpose of the present study was
therefore to determine if introducing a new tyrosine-based electron transfer pathway in human Hb resulted in
similar antioxidant properties.
Figure 1. Tyrosine electron transfer pathways in globins.
Active site structure of Hb α-subunit (A), Hb β-subunit (B), and myoglobin (C); sites of redox-active tyrosine residues are
indicated. Note that in the Hb β-subunit, the tyrosine is substituted with a phenylalanine. Mutating this to a tyrosine (βF41Y)
creates a new ascorbate reducible site. This diagram was adapted from a ﬁgure originally published in The Journal of Biological
Chemistry. Reeder, B. J. et al. Tyrosine residues as redox cofactors in human hemoglobin: Implications for engineering non
toxic blood substitutes. J. Biol. Chem. 2008; 283:30780–30787 © the American Society for Biochemistry and Molecular
Biology.
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We therefore determined the oxidative reactivity of the set of Hb mutants; we previously showed to differ in
their tyrosine electron transfer pathways [16] (Figure 1). This involved creating a new electron transfer pathway
in the β-subunit (βF41Y), deleting the existing one in the α-subunit (αY42V), and transferring the pathway
from the α- to the β-chain (αY42V/βF41Y). The properties of recombinant βF41Y are particularly interesting
as this mutation is present in the human polymorphism Hb Mequon [18].
Experimental
Protein preparation
The cloning, expression, and puriﬁcation of the recombinant Hb proteins were carried out as previously
described [16], and the proteins were stored in the stable ferrous-CO adduct forms. Native Hb was puriﬁed
from adult volunteers [11]. To make ferric Hb, the CO forms were incubated with potassium ferricyanide
(10 mM) at 4°C, and the CO was removed by constant strong light. The excess ferri/ferrocyanide was removed
from the ferric proteins by ﬁltration through a size-exclusion Sephadex G-25 column (∼5 × 0.5 cm). The con-
centration of Hb was determined by reduction in an aliquot of the ferric protein to the deoxy form using
sodium dithionite and using the extinction coefﬁcient of 133 mM−1 cm−1 at 430 nm [19]. The oxy form of the
Hb proteins was made by the addition of a slight excess of sodium dithionite to the ferric proteins, followed by
passage down a Sephadex G-25 column.
HPLC analysis
Hb samples were analyzed by reverse-phase HPLC using an Agilent 1290 HPLC ﬁtted with a diode array spec-
trophotometer. The column used was a Zorbax StableBond 300C3 250 mm × 4.6 mm ﬁtted with a 12 mm ×
4.6 mm guard column. Solvents were (A) 0.1% TFA (triﬂuoroacetic acid) and (B) acetonitrile-containing 0.1%
TFA. The gradient was initially 35% solvent B, stable for 10 min, increasing to 37% solvent B over 5 min. This
was increased to 40% solvent B over 1 min and then to 43% solvent B over 10 min. The ﬂow rate was 1 ml/
min, and the temperature was 25°C.
Oxygen afﬁnity measurements
OxyHb solutions were left overnight under helium ﬂow and in the presence of the Hayashi reducing system
before titrations [20]. The oxygen p50 and Hill coefﬁcients were obtained by measuring optical spectra after
equilibration at varying pO2 gas mixtures as previously described [21]. For in vitro conditions, p50 values were
measured in 100 mM HEPES, 1 mM EDTA, pH 7.0, 15°C; conditions more akin to that in the vasculature
(pseudo-physiological conditions) were 100 mM HEPES, 1 mM EDTA, 100 mM sodium chloride and 1.2 mM
sodium phosphate, pH 7.0, 25°C. The fractional saturation was calculated by ﬁtting the data to a linear combin-
ation of oxy, deoxy, and met Hb reference spectra.
Liposome preparation
α-Phosphatidylcholine from soybean (Type II-S, from Sigma) was added to the reaction buffer (sodium phos-
phate, 20 mM, pH 7.4) at a concentration of 5 mg/ml and then sonicated in a water bath for 15 min, until no
particulates could be seen. The ﬁnal liposome solution was maintained a pearlescent appearance. This suspen-
sion was then forced through a Northen Lipids extruder containing a membrane of size cutoff 0.1 μm using
25 mm Whatman ﬁltration membranes [22]. A minimum of 10 extrusions per sample preparation was used to
produce unilamellar liposomes of ∼100 nm.
Conjugated diene and singlet oxygen formation in liposomes
The concentration of ferric proteins used in all liposome oxidation experiments was 2 mM heme. The amount
of extruded liposomes used in all lipid oxidation assays was ∼30 ml/ml. Lipid oxidation was measured in two
ways using UV and ﬂuorescence spectroscopies. Conjugated diene formation was measured by following the
increase in absorbance at 234 nm using a Varian Cary 5E spectrophotometer. Data were collected every
7–10 min for up to 12 h. Sample volumes were 120–150 ml. Studies were performed in the presence and
absence of physiological levels of ascorbate (30 mM). Dunnett’s many-to-one comparison test was used to
determine if a mutant was different from control. In addition, due to the variability in the lipid oxidation prop-
erties between liposome preparations, in separate experiments, each protein was also compared directly with
each other in the same batch of liposomes (n = 3) using unpaired t-tests. Singlet oxygen (1O2) production was
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measured as ﬂuorescence intensity of the ﬂuorophore Singlet Oxygen Sensor Green (SOSG, Molecular Probes)
using a FLUOstar OPTIMA ﬂuorescence plate reader from BMG LABTECH. The stock solution of SOSG
(5 mM in methanol) was diluted into the reaction mixture to a ﬁnal concentration of 0.25 mM. The reactions
containing SOSG were excited at 480 nm and emission was followed at 520 nm. Data were collected every
∼3 min for up to 12 h. Sample volumes were 200 ml.
Autoxidation measurements
The rate of conversion of ferrous oxy Hb proteins to ferric Hb was monitored by UV–visible spectroscopy in
20 mM sodium phosphate (pH 7.4); for autoxidation measurements at 25°C, spectra (375–700 nm) were col-
lected for up to 48 h. For autoxidation measurements at 37°C, whole spectra were collected for up to 3 h.
Sample volumes were 1 ml. Protein concentrations were 10 mM heme. The kinetic traces were analyzed by
ﬁtting to single exponential ﬁts.
Reactions with the lipid hydroperoxide HPODE
The met forms of the Hb proteins were reacted with the 13-S hydroperoxy 9-cis, 11-trans octadecadienoic acid
(HPODE) in a stopped-ﬂow diode array spectrophotometer (Applied Photophysics, model SX-20). On rapid
mixing of the proteins with HPODE, spectral changes in the Soret and visible regions were monitored. Heme
destruction was monitored by the bleaching of the Soret peak at 405 nm. Time courses were analyzed by ﬁtting
to a double exponential curve, although in the presence of the β41 mutation the two rates were
indistinguishable.
NO dioxygenation rate
An NO solution was prepared by dissolving the NO donor Proli NONOate (Alexis Biochemicals) in a lightly
buffered degassed solution at alkaline pH. The concentration of Proli NONOate was determined using an
extinction coefﬁcient of 8500 M−1 cm−1 at 250 nm [23]. Proli NONOate was then added to a strong buffer at
neutral pH (100 mM sodium phosphate, pH 7.4) to release free NO gas; under these conditions, 1.8 molecules
of NO are released per Proli NONOate molecule. The oxy form of the relevant Hb solution (in 100 mM
sodium phosphate, pH 7.4) was placed in one syringe and the NO released from the Proli NONOate in the
other. Both the solutions were then mixed rapidly in equal volumes in the stopped-ﬂow spectrophotometer.
After mixing, the Hb concentration was 4 μM and the NO concentration was 30 μM. The absorbance changes
were monitored at single wavelengths of 405 and 430 nm over a 0.1 s time range. Owing to the speed of the
reaction, the temperature was set to 15°C.
Heme release from Hb
The vector pEMBL19-containing sperm whale myoglobin (SW Mb) H64Y/V67F was a kind gift from John Olsen
(Rice University) [24] and was then His-tagged to simplify puriﬁcation. The gene for SW Mb (H64Y/V67F) was
ampliﬁed by overhanging PCR with the primers 50-CCACATATGGTTCTGTCTGAAGGTGAATGGCAGCTG
and 50-CATGGATCCTCATTAACCCTGGTAACCCAGTTC (Euroﬁns) to introduce novel restriction sites for
NdeI and BamHI (shown in bold). The PCR fragment was restricted with NdeI and BamHI then ligated into
pET28a vector cut with the same restriction endonucleases to generate pET28a-SWMb (H64Y/V67F). To prepare
His-tagged SW Mb (H64Y/V67F), BL21 (DE3) cells were ﬁrst freshly transformed with the expression vector
pET28a-SWMb (H64Y/V67F) and subsequently grown in Luria–Bertani media at 37°C to an optical density of
∼0.8 at 600 nm. Protein expression was then induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside,
0.25 mM aminolevulinic acid, and 0.1 mM ferric citrate. Cultures were then bubbled with pure CO gas, ﬂasks
sealed thoroughly with rubber bungs and grown for a further 18 h at 27°C and 90 rpm. Cells were then
harvested by centrifugation at 4000 rpm for 20 min at 4°C. The cell paste was resuspended in 40 ml of buffer A
[50 mM NaPi (pH 7.2) and 100 mM NaCl] and cells were lysed by using an Avestin C3 Emulsiﬂex homo-
genizer. The cell lysate was cleared by centrifugation at 18 000 rpm for 30 min at 4°C and the supernatant was
ﬁltered using 0.45 μm ﬁlters before being loaded onto a 5 ml HisTrap-HP column (GE Healthcare)
pre-equilibrated with buffer A. The protein was eluted with a 50 ml linear gradient of buffer B [50 mM NaPi
(pH 7.2), 100 mM NaCl, and 1 M imidazole] and fractions containing the myoglobin were pooled. The heme
was then extracted to create apomyoglobin as described previously [25]. Heme release from the met forms of
wt and βF41Y was then measured by incubating the proteins with an excess of the heme-binding apomyoglobin
mutant H64Y/V67F and monitoring absorbance changes at 37°C in 100 mM NaPi pH 7.2, containing 0.15 M
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sucrose [24]. The fast phase of heme loss (β-subunit) was measured using single exponential ﬁts to the ﬁrst
60 s of data in a stopped-ﬂow spectrophotometer looking at the appearance of the 600 nm peak. The slow
phase (α-subunit) was also monitored at 600 nm using a Cary 5000 spectrophotometer, ﬁtting to a double
exponential and reporting the slower rate.
Kinetic reactions of deoxy Hb with nitrite
Formation of the nitrosyl complexes from the deoxy forms of the recombinant Hb proteins wt and βF41Y was
carried out in excess sodium dithionite [26]. Spectral changes were monitored in the Soret and visible regions,
and time courses were ﬁtted to 432–413 nm as single exponential ﬁts (min−1) over a 20 min time range.
Statistical analysis
The program KaleidaGraph 4 (Synergy Software) was used for analysis. In experiments involving two conditions,
unpaired t-tests were used to determine signiﬁcance. Where multiple tests or treatments were involved, ANOVA
followed by Dunnett’s many-to-one comparison test was used to determine if any condition was different from
the control.
Results
Functional properties of the βF41Y mutant
Figure 2 shows reversed-phase HPLC data for the two recombinant proteins (wt and βF41Y) and native Hb
puriﬁed from adult human volunteers. Although there is detectable heterogeneity in the recombinant proteins,
the position of the α-peaks is identical in all three proteins and there is a distinct β-peak in βF41Y, consistent
with the introduction of the mutation. All three Hb proteins showed very similar optical spectra in the deoxy,
oxy, ferric, ferryl, and ferrous-CO forms.
In human Hb, amino acid residues 41 (β) and 42 (α) are located on the C7 helix close to the heme, but yet
accessible to the external medium and the α-/β-subunit interface. Modifying residues close to the heme group or
near the subunit interface might be expected to have an adverse effect on oxygen-binding characteristics of the
protein [2]. However (Table 1), βF41Y exhibited an oxygen-binding afﬁnity within 30% of wt, either in the absence
of effector ligands or under ‘pseudo-physiological’ extracellular conditions (+1.2 mM phosphate and 100 mM Cl−).
Ferrous oxyHb is susceptible to autoxidation, producing the nonfunctional ferric (metHb) form and the
superoxide radical. Enhanced autoxidation rates and accompanying heme loss from the ferric protein have the
potential to prove problematic for HBOC applications [27]. The introduction of the βF41Y had no deleterious
effect on autoxidation rate (Table 1), either at ambient temperature or at 37°C.
Table 1 Functional properties of βF41Y Hb
Mean ± SD (n = 3).
Wt βF41Y
Oxygen binding (intrinsic, T = 25°C)
p50 (Torr) 2.61 ± 0.05 2.19 ± 0.04*
Hill coefficient 2.36 ± 0.06 1.36 ± 0.04*
Oxygen binding (+100 mM Cl−, T = 25°C)
p50 (Torr) 5.21 ± 0.07 8.89 ± 0.51*
Hill coefficient 1.31 ± 0.02 1.37 ± 0.11*
Autoxidation (h−1), T = 25°C 0.13 ± 0.02 0.12 ± 0.01
Autoxidation (h−1), T = 37°C 0.44 ± 0.08 0.39 ± 0.09
NO dioxygenation (μM−1 s−1), T = 15°C 7.8 ± 0.2 6.4 ± 0.1*
MetHb heme off (min−1), T = 37°C (β-subunit) 1.04 ± 0.04 2.08 ± 0.25*
MetHb heme off (min−1), T = 37°C (α-subunit) 0.0055 ± 0.0016 0.0054 ± 0.0006
*P < 0.05 compared with wt. For detailed conditions, see the Experimental section.
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However, the introduction of the βF41Y mutation did enhance heme release from metHb as measured by
binding to the heme-binding apomyoglobin mutant H64Y/V67F (Figure 3). Optical spectra show a clear
change in environment as the heme leaves Hb and binds to the mutant (as evidenced by the shift in the Soret
peak and the loss of the 630 nm band). At the same time, there is a growth of absorbance in the visible region
at 600 nm. Analysis of the rate of the rise in the peak revealed biphasic kinetics previously attributed to a fast
loss of heme from the β-subunit and a lower loss from the α-subunit. Consistent with this assignment, only the
fast phase showed increased heme loss in βF41Y (Table 1). The magnitude of this increase was an approximate
doubling in rate.
A decrease in the in vivo levels of the vasodilator NO is a concern following HBOC administration due to
scavenging by oxyHb. Mutations can be introduced into the heme pocket to decrease this rate by an order of
magnitude [28]. Despite lacking these modiﬁcations, the NO dioxygenation rate was still slightly decreased in
βF41Y (Table 1). More signiﬁcantly, however, this was accompanied by a doubling in the rate of reduction in
nitrite to NO catalyzed by deoxyHb (Figure 4).
Lipid oxidation and oxidative stress
The addition of metHb to liposomes initiates lipid peroxidation by an autocatalytic reaction, the extent of the
lag phase is a measure of the rate of lipid oxidation [17]. All the mutants oxidized synthetic liposomes at the
same rate in the absence of ascorbate (Figure 5). However, in the presence of physiological levels of ascorbate,
the addition of a tyrosine residue in the β-subunit signiﬁcantly decreased oxidation rates. Additional competi-
tion studies directly comparing pairs of mutants revealed that the order of the onset of this lipid oxidation
cascade in the presence of ascorbate was wt = αY42V < αY42V/βF41Y < βF41Y.
Lipid oxidation can also be measured by monitoring singlet oxygen production using the ﬂuorescent dye
SOSG (Figure 6A). The time course of lipid peroxidation following Hb addition to liposomes is identical whether
following conjugated diene formation or singlet oxygen production. The rate of singlet oxygen production is iden-
tical in wt and βF41Y metHb (Figure 6B), but is decreased in the mutant in the presence of 50 μM ascorbate
(Figure 6C). Following the addition of oxyHb, βF41Y is protective even in the absence of ascorbate (Figure 6D).
Figure 2. HPLC comparison of recombinant and native Hb.
Reversed-phase HPLC separation of heme cofactor and protein subunits from native Hb, wt recombinant Hb and the βF41Y
mutant.
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Ferric globins react directly with the HPODE; a complex set of reactions follow, involving ferryl heme that
ultimately leads to heme degradation [29]. Unlike in myoglobin, the kinetics of HPODE-induced heme degrad-
ation in Hb is biphasic, most likely due to preferential reactivity at the α- and β-subunits. The βF41Y mutant
showed increased resistance to this heme degradation (Figure 7). Analysis of the HPODE concentration
dependence revealed that the βF41Y effect was caused by removing the fast phase of damage, resulting in
monoexponential rates of heme decay.
Discussion
Tyrosine mutations and lipid oxidation
The present study demonstrates the potential advantages of engineering tyrosine-based electron transfer path-
ways as a component of a HBOC, especially if combined with antioxidants. The exemplar protein studied was
the βF41Y mutation, creating a novel protein with similar electron transfer sites facilitating ferryl reduction in
both the α- and β-subunits. It is not a priori true that introducing a new pathway for electrons to enter and
leave ferryl Hb will have new antioxidative properties; it could be argued that a new pathway could facilitate
Figure 3. Heme loss from recombinant Hb.
Heme loss from metHb and binding to the apo H64Y/V68F mutant. The spectral changes show the reaction following mixing
metHb with the apo H64Y/V68F mutant for wt (bottom) and βF41Y (top). The main ﬁgure shows the spectral changes every
13 min from t = 0 to t = 4 h. An expanded region (×7) of the visible spectra in the 600 nm region is also shown. The inset shows
the time course for the reaction in the visible region used for further kinetic analysis. Conditions: 100 mM NaPi, pH 7.2,
containing 0.15 M sucrose; T = 37°C; [Hb] = 2.5 μM; [apo mbH64Y/V68F] = 30 μM.
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Figure 4. Hb nitrite reductase activity.
Formation of nitrosyl Hb from deoxy Hb, wt, and βF41Y recombinant forms, in the presence of 0.2 mM nitrite. Conditions:
sodium phosphate buffer (20 mM, pH 7.4, 25°C); [Hb] = 5 μM. Inset: the rate (mean ± SD, n = 6) of conversion from deoxy to
nitrosyl. Asterisk indicates signiﬁcant difference from wt (P < 0.0001).
Figure 5. Effect of tyrosine mutations on Hb-catalyzed lipid peroxidation.
Liposome oxidation monitored by conjugate diene formation following the addition of recombinant metHb in the presence or
absence of ascorbate. Assay conditions: sodium phosphate (20 mM, pH 7.4, 30°C); [heme] = 2 mM; data presented as mean ±
SD, n = 9. Asterisks indicate signiﬁcant difference from wt (P < 0.05).
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Figure 6. Singlet oxygen production catalyzed by recombinant Hb.
Changes in singlet oxygen (ﬂuorescence) and conjugated diene (absorbance) formation following the addition of metHb to
liposomes (A). Comparison of wt and βF41Y metHb addition in the absence (B) and presence (C) of 50 μM ascorbate. Addition
of wt and βF41Y oxyHb to liposomes (D). Assay conditions: sodium phosphate (20 mM, pH 7.4, 30°C); [heme] = 2 mM; [SOSG]
= 0.25 mM. Data presented as mean ± SD, n = 8.
Figure 7. Reaction of the lipid peroxide HPODE with recombinant Hb.
Addition of 32 μM HPODE to metHb (wt and βF41Y). Time courses of heme damage (inset) were ﬁt to double exponentials and
plotted against [HPODE]. Conditions: sodium phosphate (20 mM, pH 7.4); [heme] = 2 μM after mixing; T = 25°C.
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oxidative damage induced by Hb, making it easier for nearby lipids and proteins to be modiﬁed by the ferryl
species. However, at least in the case of lipids, that did not seem to be the case. The onset of liposome oxida-
tion by metHb was unchanged whether the electron transfer pathway was removed in the α-subunit or added
to the β-subunit. However, in the presence of plasma antioxidants, such as ascorbate, the βF41Y mutation pro-
tected the liposomes from damage. This is consistent with our studies in Aplysia myoglobin, where we intro-
duced two novel, fast, tyrosine-based electron transfer pathways [17]. Both of these protected against liposome
oxidation, but again only in the presence of ascorbate.
Rather than being catalyzed by Hb ferric/ferryl redox cycling [10], liposome oxidation could be initiated dir-
ectly by the ferric ion alone in metHb or indirectly via heme iron releasing from the protein and entering the
lipid bilayer. The results in the present paper argue against this. Ascorbate is protective against lipid peroxida-
tion in the presence of our mutants. Yet, ascorbate reduction in metHb [11] is slow compared with ascorbate
reduction in ferryl Hb, and βF41Y does not enhance this already very slow rate (results not shown). In the case
of heme insertion into the liposomes, the βF41Y shows slightly enhanced heme release (Table 1) and so, if
anything, would be expected to be more pro-oxidative in this system.
There are two alternative mechanisms by which tyrosine mutations could increase the lag phase of lipid oxi-
dation in the presence of ascorbate. The ﬁrst is by direct reduction in the ferryl species that react with lipid per-
oxides. However, it is also theoretically possible that the tyrosine residue could provide a pathway whereby the
unpaired electron on a lipid peroxide radical is transferred to ascorbate via Hb. In the latter case, electron trans-
fer to/from the heme iron would not be directly involved. These mechanisms are not mutually incompatible
and could operate synergistically. This could explain why in Aplysia Mb introducing new tyrosine residues
enhances the reduction in ferryl Mb and decreases lipid oxidation, but the two activities do not closely correl-
ate, that is, the mutant that reduces ferryl fastest is not the one that has the greatest inhibition of lipid oxida-
tion. It could also explain why moving the tyrosine residue from α42 to β41 is partially protective in the
presence of ascorbate (the present paper), despite only limited effects on the ferryl reduction rate [17].
Liposome oxidation catalyzed by oxyHb appears to be slower in βF41Y even in the absence of ascorbate. The
reason for this could also be linked to the idea that βF41Y is in a particularly apposite environment to donate
electrons. The reaction of oxyHb with liposomes is more complex than that of metHb, as not only does the
heme react with lipid peroxides, but there is also a contribution from the autoxidation rate (which itself forms
superoxide radicals). The autoxidation rate is slightly slower in βF41Y (Table 1) and this could at least partially
explain the observed protection in the oxyHb mutant. However, there also seems to be a direct effect of lower
reactivity with lipids. This is shown by the slower reaction of βF41Y metHb with the lipid peroxide HPODE.
Globin reactions with HPODE are mechanistically complex [29]. Therefore, in the present paper, we limited
ourselves to looking at the simpler endpoint of heme destruction. In wt Hb, this is biphasic. However, in the
mutant, the faster phase is lost. The simplest explanation for this is that the presence of a redox-active tyrosine
close to the heme enables the safe removal of an oxidizing species. Although we have previously suggested that
the ﬁnal stable protein radical following peroxide interaction with Hb is at βTyr145 [30], it is likely that the
tyrosine 42 in the α-Hb subunit (or its homologous location in other globins) is the initial destination for the
radical once it leaves the porphyrin ring [14,31,32]. Lacking such a tyrosine, the β-subunit may be more suscep-
tible to heme destruction by HPODE. In this simple model, the biphasic reactivity seen in the present paper
would be a simple consequence of differing reactivity at the α- and β-subunits, with the βF41Y mutation
equalizing the relative rates.
Taken together, these results strongly suggest that the addition of a redox-active heme-accessible tyrosine to
the β-subunit of human Hb would be a useful component of a future recombinant HBOC designed to decrease
ferryl heme reactivity, especially when combined with a suitable reductant.
βF41Y as a component of a HBOC
The βF41Y mutation is functional in vivo as it has been described in a human polymorphism (Hb Mequon).
The clinical subject was not anemic, and the blood oxygen afﬁnity was normal and sensitive to the effector
BPG [18]. The Hb Mequon patient was suffering from severe hemolysis following a viral illness treated with
acetaminophen. However, this was an isolated incident and none of the family relatives carried any hemato-
logical disorder. Although it is possible that there is some latent instability in Hb Mequon, it remains unclear
whether there is any causal link between βF41Y and the hemolytic event. In any event, the existence of such a
stable polymorphism in an otherwise healthy 34-year-old patient suggests that βF41Y is a relatively benign
polymorphism. Although there may be subtle differences between the recombinant and native version of this
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protein, the data in the present paper support the idea that the βF41Y mutation is relatively benign; perhaps,
the tendency for faster heme loss is ameliorated by enhanced antioxidative properties? In any event, there
appears no reason a priori to dismiss βF41Y as a component of an acutely administered HBOC.
The oxygen afﬁnity and autoxidation rate of βF41Y have been studied extensively under a range of condi-
tions by the groups of Baudin-Creuza and Marden [33,34]. They showed a decrease in oxygen afﬁnity com-
pared with Hb A (the native protein puriﬁed from blood) and attributed this to stabilization of the T-state
conformation. Our study is consistent with theirs in that a decrease in oxygen afﬁnity was observed in the pres-
ence of 100 mM chloride. However, a slight increase in afﬁnity in the absence of chloride was seen. Part of the
difference is possibly because we are comparing our protein to the recombinant wt rather than Hb A; indeed,
most of the difference seen in the absence of chloride is due to differences in our wt compared with their Hb
A, rather than differences in the mutant itself. In general, when analyzing mutant Hbs, we caution against com-
paring solely against native Hb A, as recombinant proteins can be modiﬁed during growth or incompletely pro-
cessed (for example, due to incomplete cleavage of the N-terminal methionine). In this regard, we found some
reduction in co-operativity in βF41Y compared with previous publications [34]. It is possible that this was due
to protein heterogeneity as in our hand values of the Hill coefﬁcient in different preparations are more variable
than those for the oxygen afﬁnity; measurements on wt Hb from ﬁve different preparations showed robust p50
values under our ‘pseudo-physiological’ conditions (5.66 ± 0.42 mm Hg), but rather variable numbers for the
Hill coefﬁcient (2.23 ± 0.42).
In contrast with previous results, which showed a small increase in the autoxidation rate when compared
with Hb A [35], we found that when compared with wt, βF41Y had a slightly decreased rate of autoxidation.
Measurement of this rate is highly dependent on protein concentration and the nature of the analysis [35], and
we would not put too much weight on these small differences. Of more concern for an HBOC is the rate of
heme loss, which has not previously been measured in βF41Y. Heme loss from extracellular Hb is a concern in
HBOC, particularly as free heme has recently been shown to act as a damage-associated pattern molecule, acti-
vating the immune response system via the TLR-4 receptor [36]. A small increase in this rate in the β-subunit
was observed, which is of some concern. It is likely that this increased heme loss will need to be addressed in
any ﬁnal HBOC product, either by the additional mutants designed to ‘waterproof’ the heme pocket [37] or by
subsequent chemical modiﬁcations. Alternatively, F41Y is not the only place, where a tyrosine can be intro-
duced into the β-chain to enhance ferryl reduction. We have shown the same effect with another mutation
introduced on the surface of Hb, βK66Y [38]; although this mutant is not oxidatively stable, it has decreased
heme loss compared with wt. Therefore, the ability to enhance ferryl reduction does not automatically correlate
with enhanced heme loss, suggesting that a different tyrosine mutation to βF41Y could be an even better
starting material for a new HBOC.
It appears unlikely that surface-accessible tyrosine, even those close to the heme like βF41Y, would signiﬁcantly
affect the NO dioxygenation activity as this generally requires modiﬁcation of the heme pocket [28]. This is
indeed what was found; F41Y only showed a small decrease in NO scavenging. However, it did signiﬁcantly
enhance the nitrite reductase rate. Although this is known to be under allosteric control, and thus a function of
the oxygen p50 [39,40], the βF41Y mutation affected the intrinsic nitrite reductase rate of T-state Hb independent
of allostery. The three-fold increase in this rate in βF41Y is similar to the increase seen in fetal compared with
adult Hb [41,42]; it is not clear if these differences have a kinetic or thermodynamic explanation.
The co-administration of nitrite has been suggested as being beneﬁcial for maintaining NO levels following
HBOC addition. However, enhanced metHb formation makes this problematic and in vivo results have not
been promising [43]. The results from βF41Y suggest that — like NO dioxygenation — the nitrite reductase
activity of Hb may be amenable to manipulation, raising the possibility of maintaining NO levels without
enhancing metHb formation.
The idea of using βF41Y as part of a HBOC has been suggested previously [34]. However, the design ration-
ale [35] was the engineering of a lower intrinsic oxygen afﬁnity (by stabilizing the T-state), rather than enhan-
cing the interaction with external reductants. The work here suggests that F41Y possesses an additional key
property; in the presence of suitable reductants, βF41Y has superior antioxidative properties compared with wt
Hb. This property is likely to be shared by other tyrosine mutations [17].
Conclusion
In summary, the addition of a new surface-accessible tyrosine residue in the β-subunits renders Hb less oxida-
tively damaging without compromising its ability to act as an extracellular oxygen carrier. This enhanced
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reactivity with plasma antioxidants is not just a function of βF41Y in human Hb. We have shown even larger
effects after introducing tyrosine residues to a variety of novel sites on the surface of Aplysia myoglobin [17].
Historically, the lack of a clinically viable HBOC product has been seen as due to adverse side effects rather
than a lack of functionality in oxygen transport [44]. This report demonstrates that the introduction of new
tyrosine electron transfer pathways in human Hb renders it less pro-oxidant. Alternative attempts to render Hb
less oxidatively damaging have included cross-linking to antioxidant enzymes [45] or cellular antioxidants [46].
Protein engineering has the potential to deliver similar beneﬁts in a more deﬁned and homogenous product.
We suggest that appropriate redox-active tyrosine mutations could form the basis for a new generation of
HBOC that retain the functionality of previous products, but limit the adverse side effects.
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